Healthy
Conditions
Brief summary
To compare the oral bioavailability and rate of absorption of four prototype extended-release (ER) formulations with BI 11634 (single doses) to immediate-release (IR) tablets in healthy male volunteers.
Interventions
DRUGBI 11634 ER formulation A
DRUGBI 11634 ER formulation B
DRUGBI 11634 ER formulation M
DRUGBI 11634 ER formulation C
DRUGBI 11634 IR tablet
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
21 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Caucasian males according to the following criteria, based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG, clinical laboratory tests * Age ≥21 and ≤45 years * Haemoglobin within the normal ranges. * Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2 * Signed and dated written informed consent prior to admission to the study in accordance with good clinical practice (GCP) and the local legislation
Exclusion criteria
* Relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Relevant surgery of gastrointestinal tract * History of any bleeding disorder or acute blood coagulation defect, for the subject itself or any person of his family as far as known * History of gastric ulcera and cholecystectomy * Occult blood in faeces * Relevant diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts * Relevant chronic or acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial * Use of acetylsalicylic acid or any other non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of study start until the end of study * Participation in another trial with an investigational drug within two months prior to administration or during the trial * Alcohol abuse (more than 40 g/day) * Drug abuse * Blood donation (more than 100 mL within four weeks prior to administration or during the trial) * Excessive physical activities (within one week prior to administration or during the trial) * Any laboratory value outside the reference range that is of clinical relevance * Inability to understand and comply with protocol requirements, instructions and protocol stated restrictions, the nature, scope and possible consequences of the study * Subjects with a history within the past six weeks of closed-head or torso trauma or deceleration injury such as an automobile accident or fall from a significant height
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 48 hours after drug administraton |
| Cmax (maximum measured concentration of analyte in plasma) | up to 48 hours after drug administraton |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| λz (terminal rate constant in plasma) | up to 48 hours after drug administration | — |
| t1/2 (terminal half-life of the analyte in plasma) | up to 48 hours after drug administration | — |
| MRTpo (mean residence time of the analyte in the body after oral administration) | up to 48 hours after drug administration | — |
| CL/F (apparent clearance of the analyte in the plasma after extravascular administration) | up to 48 hours after drug administration | — |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 48 hours after drug administration | — |
| Fluctuation parameter Cmax/C24 ratio | up to 48 hours after drug administration | — |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) | up to 48 hours after drug administration | — |
| Number of subjects with adverse events | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant findings in vital signs (blood pressure, pulse rate) | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant findings in ECG | up to 8 days after last drug administration | — |
| Number of subjects with clinically significant findings in laboratory tests | up to 8 days after last drug administration | — |
| Assessment of tolerability by investigator on a 4-point scale | up to 8 days after last drug administration | — |
| % Inhibition of Factor Xa | up to 48 hours after drug administration | by Russel's Viper Venom test (RVV) |
| Maximum prolongation of blood coagulation time | up to 48 hours after drug administration | by HepTest® (Haemachem Inc.) |
| tmax (time from dosing to the maximum concentration of the analyte in plasma) | up to 48 hours after drug administration | — |
Outcome results
None listed